Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631592 · ClinicalTrials.gov registry record · Phase 1
GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00631592 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 44 participants.
The verdict
NCT00631592, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a repeat dose escalation study of GSK1349572 followed by a relative bioavailability study comparing tablet and suspension formulations in healthy volunteers.
Interventions
- DRUG GSK1349572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631592
The ClinicalTrials.gov registry entry for NCT00631592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1349572 is the first listed.
NCT00631592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631592 about?
NCT00631592 is a clinical study titled "GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study". This is a repeat dose escalation study of GSK1349572 followed by a relative bioavailability study comparing tablet and suspension formulations in healthy volunteers.
What is the current status of trial NCT00631592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2008-02. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00631592?
The interventions under investigation include: GSK1349572 (DRUG).
Who is sponsoring clinical trial NCT00631592?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.